Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

3T FEDERAL SOLUTIONS LLC AUSTIN 78721

UEI: SLED_4C4EF5F24CAE0237

3T FEDERAL SOLUTIONS LLC AUSTIN 78721 is a federal contractor, registered under UEI SLED_4C4EF5F24CAE0237. It has been awarded $503,172 across 6 federal contracts. Primary work spans In-Vitro Diagnostic Substance Manufacturing and Pharmaceutical Preparation Manufacturing. Top awarding agencies include National Cmop Office (36C770).

Contact Information

Registration and classification details

Registration

UEI Code

SLED_4C4EF5F24CAE0237

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

National Cmop Office (36C770)$503.2K100%

Awards by NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing$392.6K78%

325412 - Pharmaceutical Preparation Manufacturing$110.6K22%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in 3T FEDERAL SOLUTIONS LLC AUSTIN 78721's top NAICS codes and agencies

BUPIVACAINE AND EPINEP

Solicitation # SPE2DP-26-T-4389

The contract specifies the procurement of bupivacaine and epinephrine injection in 1.8 mL cartridges containing 0.500% w/v bupivacaine hydrochloride and 0.005 mg epinephrine per mL (1:200,000), supplied in lots of 50 cartridges per container, with a total quantity of two containers. The product must be stored at controlled room temperature between 15 and 30 degrees Celsius and maintain a minimum shelf life of 15 months at the time of delivery to the first government activity, despite an 18-month maximum shelf life. All packaging must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must be commercially packaged to ensure protection from damage and safe transport via common carrier at lowest cost to the destination. The material is not considered hazardous under FED-STD-313 and must be packaged in accordance with ASTM D3951, though all DLA Technical and Quality Requirements take precedence. Mercury or mercury-containing compounds are prohibited in direct contact with the product, except for functional uses in batteries, instruments, or sensors as permitted under NAVSEA guidelines. Delivery is required FOB destination within 20 days of order placement to the USS MIGUEL KEITH (ESB-5) in San Diego, California, with no tolerance for quantity variance. The item is identified by NSN 6505-01-189-3973 and referenced under Purchase Request 7017681406, with multiple approved manufacturers listed including DENTAL HEALTH PRODUCTS INCORPORATED, CARESTREAM DENTAL LLC, PATTERSON DENTAL, HENRY SCHEIN, INC., and BENCO DENTAL SUPPLY CO. All packaging and labeling must adhere to DLA Packaging Requirements for Procurement and palletization standards, and shipment details include vessel-specific transport instructions and government-only tracking identifiers.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

CARPROFEN TABLETS

Solicitation # SPE2DP-26-T-4392

Carprofen Tablets 100mg are chewable nonsteroidal anti-inflammatory, analgesic, and antipyretic tablets specifically formulated for dogs, supplied in bottles of 60 tablets each. The product is regulated by the FDA and must comply with the DLA Master List of Technical and Quality Requirements, including packaging standards per Medical Marking Standard No. 1 and MIL-STD-2073-1E, with no tolerance for quantity variance. It is classified as a Type I (Code Q) item with a fixed 36-month shelf life that is non-extendable and must be stored at controlled room temperature between 15–30°C (59–86°F). The item is procured under solicitation SPE2DP-26-T-4392 with a delivery requirement of 20 days FOB destination, and inspection and acceptance occur at the delivery point. Only approved manufacturers including Zoetis Inc., Covetrus North America, LLC, and Patterson Veterinary Supply, Inc. with specified part numbers are eligible, and all supplies must be properly marked in accordance with government standards. The contracting official must submit a referral through EBS to confirm product suitability before award, and the item is identified by NSN 6509014874464 under the Department of Defense’s Medical Supply Chain PHARM FSA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

PENTOBARBITAL SODIU

Solicitation # SPE2DP-26-T-4387

Pentobarbital Sodium Injection, Veterinary, is a Schedule II controlled substance with high abuse potential, supplied in 250ml vials containing 6 grains of sodium pentobarbital for euthanasia purposes. Each unit is classified as a Type I (Code M) item with a non-extendable shelf life of 24 months and must be stored under vault conditions at room temperature in compliance with DEA regulations for Schedule II drugs. The product is regulated by the FDA and must be labeled and accompanied by Safety Data Sheets (SDS) aligned with OSHA’s Hazard Communication Standard and the Globally Harmonized System, effective after June 1, 2015. Labeling and documentation must conform to 29 C.F.R. 1910.1200, and suppliers are required to train employees on these requirements. All packaging must adhere to MIL-STD-2073-1E and the latest Medical Marking Standard No. 1, with government identification removed from non-accepted supplies per RQ011. The contract, issued under solicitation SPE2DP-26-T-4387, specifies a quantity of two units, each costing $2.00, for a total price of $4.00, with delivery required within five days FOB destination. Inspection and acceptance occur at the delivery point, with zero tolerance for quantity variance. The NSN is 6509-01-485-6206, and the item is procured under the DOD’s authorized unit of issue. The point of contact for the procurement is Shairy M. Cartagena of the Department of Defense’s Medical Supply Chain PHARM FSA, with performance taking place at Lackland AFB. The product is supplied by Patterson Veterinary Supply, Inc. and Covetrus North America, LLC, identified by respective part numbers, and the acquisition falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

LIDOCAINE HYDROCHLORID

Solicitation # SPE2DP-26-T-4390

Lidocaine Hydrochloride and Epinephrine Injection, USP, in a 2% concentration with a 1:100,000 epinephrine ratio, is supplied in 1.7 mL cartridges packaged in units of 50 per PG, with a total shelf life of 15 months. A minimum of 13 months of remaining shelf life is required at the time of receipt by the first government activity, and the product must be stored at controlled room temperature below 25°C (77°F), protected from light and prevented from freezing. It is labeled as latex-free and intended exclusively for local dental anesthesia via nerve block or infiltration. Packaging must conform to Commercial standards as specified in DLA’s packaging requirements, with all units sealed in protective containers and shipped in exterior containers suitable for safe delivery by common carrier at the lowest cost. Labeling and marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and all packaging must adhere to the DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951. Hazardous material shipping requirements specified in FED-STD-313 and TQ requirement IP025 apply if applicable, and palletization must follow RP001 guidelines. The product is regulated by the FDA and requires pre-award confirmation through EBS referral. The contract specifies three line items under solicitation SPE2DP-26-T-4390, all referencing the same NSN: 6505-01-597-1328, with delivery due within five days of award and FOB destination. Quantity requirements total 12 PGs (1200 cartridges), distributed across three delivery points: USS Tulsa (LCS-16), USS Princeton (CG-59), and the Carrier Outfitting Material Support Center in Suffolk, VA. Shipment must be sent by the fastest traceable means, prohibiting parcel post, and each order must include the correct unit of issue and quantity per unit pack. The solicitation was posted July 30, 2026, with responses due by August 5, 2026, and required delivery dates range between August 3 and August 4, 2026. Vendors are identified as Darby Dental Supply, Henry Schein Inc., and Benco Dental Supply Co., with specific part and N

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

WATER FOR INJECTION, ST

Solicitation # SPE2DP-26-T-4380

Water for Injection, Sterile, USP, is supplied in 1000ml plastic bags, packaged in units of 12 bags per package, with a total procurement quantity of 2 packages. The item is regulated by the FDA and requires strict adherence to medical marking standards, specifically the latest edition of Medical Marking Standard No. 1, as defined by DLA. It must be stored at controlled room temperature and carries a non-extendable shelf life of 24 months, classified as a TYPE I (CODE M) item under DLA requirements. All packaging and labeling must comply with MIL-STD-2073-1E and the DLA Packaging Requirements for Procurement, with government identification removed from non-accepted supplies. The product is sourced from approved manufacturers including B. BRAUN MEDICAL INC and ICU MEDICAL, INC, each with designated NDC numbers. Delivery is required FOB destination within five days of contract award, with zero variance allowed in quantity. Inspection and acceptance occur at the delivery point, with the NSN 6505-01-386-9046 and procurement reference PR 7017669520. The solicitation, issued under SPE2DP-26-T-4380, was posted on July 30, 2026, with responses due by August 5, 2026, and is managed by the Department of Defense's Medical Supply Chain Pharm FSA, with primary point of contact James Foggie.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ERYTHROMYCIN OPHTHALMI

Solicitation # SPE2DP-26-T-4394

ERYTHROMYCIN OPHTHALMIC OINTMENT USP is a sterile, topical ointment containing 5 mg of erythromycin per gram in a base of mineral oil and white petrolatum, intended for ophthalmic use only. Each unit is packaged as a single-dose tube containing 3.5 grams of ointment, with 24 tubes per package, defined as the unit of issue. The product must have a minimum of 31 months of remaining shelf life upon receipt by the first government activity, as its total shelf life is 36 months and is non-extendable. Storage requirements mandate controlled room temperature between 15°C and 30°C (59°F–86°F), with protection from excessive heat and freezing. All packaging and labeling must strictly adhere to Medical Marking Standard No. 1A dated February 4, 2013, superseding MIL-STD-129, and must comply with DLA’s Master List of Technical and Quality Requirements. The ointment is regulated by the FDA and must be marked and shipped in accordance with commercial packaging standards, specifically ASTM D3951 if not classified as hazardous under FED-STD-313; however, DLA requirements take precedence over all other standards. Each shipment must be delivered FOB destination within five days, using the fastest traceable means, excluding parcel post, to the specified delivery point at Fort Lewis, WA. The product is identified by NSN 6505-01-189-7090, with a single purchase order quantity of one package, and the manufacturer is PADAGIS US LLC under NDC 00574-4024-39.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

RINGER'S INJECTION, LAC

Solicitation # SPE2DP-26-T-4395

RINGER'S INJECTION, LACTATED, USP, 1000ML, in packs of 12 units per case, is being procured under contract SPE2DP-26-T-4395 with a total order of 7 packing groups, equivalent to 84 individual units. The product is manufactured by B. Braun Medical Inc. with NDC 00264-7750-00 and is subject to FDA regulation. Packaging must comply strictly with Medical Marking Standard No. 1, superseding all references to MIL-STD-129, and must ensure protection from damage and breakage during transit. Each unit must be sealed and packed in commercial shipping containers suitable for safe delivery via common carrier at the lowest cost to the specified destination, which is FPO AP 96675. The item has a non-extendable shelf life of 30 months and must be stored at room temperature (25°C), with brief exposure up to 40°C permitted. Packaging must adhere to DLA’s RP001 requirements and the latest DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951. No hazard classification applies under FED-STD-313, so commercial packaging per ASTM D3951 is acceptable but subordinate to DLA standards. Delivery is required within 20 days of contract award, with zero quantity variance allowed, and inspection and acceptance occur at the delivery point. The unit of issue is packing group (PG), with each PG containing 12 units. All markings, labeling, and palletization must conform to specified DLA and federal standards, and shipping instructions must follow DLAD Proc Note C19 and C20. The solicitation closed on August 5, 2026, with an original required delivery date of August 3, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

POVIDONE-IODINE CLEANS

Solicitation # SPE2DP-26-T-4384

POVIDONE-IODINE CLEANSING SOLUTION, USP, with 7.5% active ingredient, is procured for external use only in 1-gallon bottles, designated by the unit of issue BT, with a total shelf life of 36 months; at least 31 months of shelf life must remain upon delivery to the first government activity. Storage must be maintained at 25°C (77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The product is regulated by the FDA and must comply with all applicable DLA Master List of Technical and Quality Requirements, including packaging standards RP001 and labeling mandates under the Hazard Communication Standard, requiring Safety Data Sheets and GHS-compliant labels submitted for approval prior to award. All packaging must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and be commercially sealed to prevent damage, with palletization following DLA guidelines. The item is classified as hazardous per Fed-Std-313 and must be packaged according to TQ requirement IP025. Five 1-gallon units are required under two contract line items, both with identical NSN 6505009947224, each priced individually, with zero variance allowed in quantity. Delivery is FOB destination within 20 days, inspected and accepted at the destination point. Shipments must be traceable and dispatched via freight, not parcel post, with delivery address to USS HARPERS FERRY LSD 49, FPO AP 96665. The original required delivery date is August 3, 2026, and the product must be labeled with the specified manufacturer part numbers from Cardinal Health 200, LLC and Purdue Pharma LP. All documentation, including SDS and labels, must align with 29 C.F.R. 1910.1200, and supplier employees must be trained on updated hazard communication requirements. The contract is issued under solicitation SPE2DP-26-T-4384 with the NAICS code 325412 and is managed by the Department of Defense's Medical Supply Chain PHAR FSA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

WATER FOR IRRIGATION, S

Solicitation # SPE2DP-26-T-4383

This contract specifies the procurement of sterile irrigation water, USP, in 1000 mL semi-rigid plastic containers with screw caps, optionally featuring a hanging device, intended exclusively for sterile irrigation, washing, rinsing, and dilution purposes and not for parenteral injection. The product must be distilled, nonpyrogenic, and packaged in units of issue consisting of 12 containers per package, with a non-extendable shelf life of 36 months. It is regulated by the FDA and must comply with the latest edition of Medical Marking Standard No. 1 and MIL-STD-129 for labeling and packaging, adhering to DLA’s Master List of Technical and Quality Requirements. Storage must be maintained at controlled room temperature between 20°C and 25°C, and protection from freezing and excessive heat is mandatory. The item is supplied by Baxter Healthcare Corporation under part number 2F7114 and NDC 00338-0004-04, with a unit price and total price to be determined upon award. Delivery is required FOB destination within 20 days of contract award, with zero variance allowed in quantity acceptance, and inspection and acceptance occur at the delivery point. The shipment is destined for USS ILLINOIS SSN-786 at FPO AP 96694, and compliance with DLA packaging and transportation protocols, including Fed-Std-313 and ASTM D3951 for non-hazardous materials, is required. All packaging must be palletized in accordance with RP001 and marked in full compliance with DLA standards. The solicitation, identified as SPE2DP-26-T-4383, was posted on July 30, 2026, with responses due by August 5, 2026, and the original required delivery date is August 3, 2026. The contracting official must submit a referral through EBS to confirm regulatory status, including bidder and manufacturer details, prior to award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

CONTROL LOOP SET

Solicitation # SPE2DS-26-T-291B

The CONTROL LOOP SET is a microbiology product containing Streptococcus pyogenes ATCC 19615 culture loops, provided in packages of five units per PG, and designed for use in controlled laboratory settings. It requires strict refrigeration storage between 2 to 8 degrees Celsius and must not be frozen. The item has a non-extendable shelf life of 15 months, with no more than two months elapsed between the date of manufacture and delivery to the government. Labeling must include the date of manufacture, expiration or retest date, and the contract or lot number, in compliance with the latest Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must meet commercial standards, ensuring protection against damage during transit, and must be suitable for safe delivery by common carriers at the lowest cost to the specified point of delivery. All packaging and marking must adhere to the latest MMS1C guidelines. The product is subject to DLA packaging requirements and must not carry government identification if rejected. This item falls under NSN 6550-01-691-8597 with a purchase quantity of one PG and a delivery expectation of 20 days after award. The solicitation is issued under contract SPE2DS-26-T-291B with a response deadline of August 5, 2026, and is managed by the Department of Defense’s Medical Supply Chain for the Office of Surgical and Medical Support. Technical and quality requirements referenced under R and I numbers are governed by the DLA Master List of Technical and Quality Requirements, and the contract incorporates provisions for covered defense information and federal procurement protocols.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

POVIDONE-IODINE TOP

Solicitation # SPE2DP-26-T-4386

Povidone-Iodine Topical Solution, USP, in a 10 percent concentration, 1/2 fl oz (15 mL) bottle, is being procured in units of 50 bottles per parcel grouped under the unit of issue “PG.” The contract requires a total of two PG units, with one unit having a required delivery date of August 3, 2026, and the other by August 4, 2026, both subject to a 20-day delivery window. At the time of delivery to the first government activity, each shipment must retain at least 31 months of the full 36-month shelf life, which is non-extendable. Packaging and labeling must strictly adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and all units must be commercially packaged in sealed containers that protect against damage, with palletization conforming to DLA’s packaging requirements. The product is regulated by the FDA and classified as a critical application item, requiring compliance with all applicable DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951 or other commercial standards. Hazardous material handling guidelines under FED-STD-313 and IP025 apply if applicable, but the item is generally expected to be commercially packaged. Shipments must be sent via traceable means, explicitly prohibiting parcel post, and delivered to designated military freight addresses in San Antonio, Texas. The manufacturer is Purdue Pharma LP with NDC 67618-0150-05, and the NSN is 6505-00-914-3593. The contracting official must submit a referral via EBS for product confirmation, including manufacturer and bidder details. Total quantity ordered is 100 bottles, with a unit price of $1.00 per PG, resulting in a total contract value of $2.00. All packaging must be marked in accordance with established government standards, and no quantity variance is permitted.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DEXTROSE INJECTION

Solicitation # SPE2DP-26-T-4393

Dextrose Injection 5% USP, 1000 mL, is a sterile, nonpyrogenic intravenous solution supplied in single-dose plastic bags, each containing 5 grams of anhydrous dextrose USP in water for injection USP, and is labeled as latex-free. The product is intended solely for intravenous administration and is packaged in units of 12 bags per package, with a strict shelf-life requirement of 30 months that is non-extendable. Storage must be maintained between 20°C and 25°C (68°F to 77°F), protected from freezing and excessive heat, in compliance with USP controlled room temperature standards. The item is subject to the latest DLA Master List of Technical and Quality Requirements, and packaging must adhere to MIL-STD-129 and the Medical Marking Standard No. 1, with no deviation permitted from DLA specifications even if ASTM D3951 is otherwise applicable. The product is not classified as hazardous under FED-STD-313, so commercial packaging standards are secondary to DLA requirements. Two separate delivery lines are specified under contract SPE2DP-26-T-4393, each for one package of 12 units, to be delivered FOB destination within five days of shipment, with no tolerance for quantity variance. Deliveries are directed to two U.S. Navy vessels, USS Jefferson City and USS Delaware, with shipping instructions requiring traceable transport and explicitly prohibiting parcel post. The contract specifies a required delivery date of August 3, 2026, and includes government-specific identifiers, logistics codes, and procurement data tied to the NSN 6505-01-330-6252, with full technical and quality compliance governed by DLA directives that supersede all other standards.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DOXYCYCLINE HYCLATE

Solicitation # SPE2DP-26-T-4150

The contract specifies the procurement of Doxycycline Hyclate Tablets, USP equivalent to 100 mg of doxycycline, packaged in bottles of 100 tablets each, with a total quantity of eight bottles to be delivered within 20 days after award. The item is regulated by the FDA and has a non-extendable shelf life of 36 months as a TYPE I (CODE Q) item. Packaging must comply with commercial standards as defined in the procurement document, with each unit sealed in a protective container and shipped in commercial exterior containers suitable for safe transport at the lowest cost. Medical items are subject to Medical Marking Standard No. 1, which supersedes MIL-STD-129 for all marking and labeling requirements, including barcoding and traceability, and must be followed strictly. Palletization and shipping must adhere to RP001 DLA packaging requirements, and if the product is classified as hazardous under FED-STD-313, it must be packaged per IP025; otherwise, ASTM D3951 applies but is subordinate to all DLA technical and quality requirements. The delivery is FOB destination to Fort Bragg, North Carolina, and shipments must be sent via traceable means, explicitly prohibiting the use of parcel post. The contract mandates electronic submission of payment requests through WAWF and requires compliance with numerous FAR and DFARS clauses covering equal opportunity, trafficking prohibitions, cybersecurity, hazardous materials, export controls, and small business representations. Offerors must hold valid UEI and CAGE codes and disclose any socioeconomic status, including eligibility under small business programs. All packaging and labeling must be consistent with Medical Marking Standard No. 1A dated February 4, 2013, and suppliers must ensure product integrity by storing at controlled room temperature between 20 to 25°C and protecting from light and moisture. The item’s NDC is 62135-0626-01, and the NSN is 6505-01-600-3042, with no tolerance allowed for quantity variance. The requirement to confirm bidder and manufacturer details through EBS referral to the product specialist must be fulfilled by the contracting officer prior to award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ISOPROPYL ALCOHOL

Solicitation # SPE2DP-26-T-4385

ISOPROPYL ALCOHOL USP, also known as rubbing alcohol, is a 99% isopropanol solution packaged in a single bottle containing 473 milliliters, equivalent to one pint or 16 ounces, intended for over-the-counter use. The product is classified as a hazardous material due to its high flammability, requiring storage between 20°C and 25°C (68°F to 77°F) in accordance with USP controlled room temperature standards. It poses serious eye irritation risks and may cause drowsiness or dizziness, necessitating strict precautions such as keeping it away from heat, sparks, open flames, and hot surfaces, with no smoking allowed. Compliance with Department of Defense Logistics Agency packaging and hazardous materials requirements is mandatory, including adherence to 49 CFR and ICAO regulations. A current Material Safety Data Sheet (MSDS) must accompany each shipment and be submitted electronically to DLA.MSDS@DLA.MIL along with the required cover sheet (P-75). The item is regulated by the FDA and carries the NSN 6505-00-205-6513. The solicitation, issued under SPE2DP-26-T-4385, has a response deadline of August 5, 2026, with a required delivery within 20 days of award. The contracting officer must submit a referral in EBS for product specialist confirmation prior to award, including bidder and manufacturer details. Packaging, labeling, and handling must comply with DLA’s Master List of Technical and Quality Requirements, and any government identification must be removed from non-accepted supplies. The point of contact for inquiries is Shairy M. Cartagena, with a place of performance specified in Tampa, Florida.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TOLNAFTATE POWDER, U

Solicitation # SPE2DP-26-T-4391

The contract specifies the procurement of TOLNAFTATE POWDER, USP 1%, in 45-gram units, identified by NSN 6505-01-480-7897 and NDC 57896-0199-45, with a total quantity of seven units—one unit under CLIN 0001 and six units under CLIN 0002—all requiring delivery within 20 days FOB destination with zero variance allowed. The item is classified as a Type I (Code Q) medical supply with a strictly non-extendable 36-month shelf life. All packaging must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and must meet DLA’s Master List of Technical and Quality Requirements, which take precedence over ASTM D3951 or Fed-Std-313. The product must be commercially packaged in sealed unit containers that protect against damage, with exterior shipping containers suitable for safe and economical transport via common carrier to the designated FPO address. Palletization must follow RP001 packaging requirements, and the unit of issue is defined as BT, equal to 45 grams. Hazardous material protocols apply only if warranted by Fed-Std-313; otherwise, commercial packaging standards govern. Shipping must avoid parcel post and utilize the fastest traceable means, with specific FOB and DLA vendor shipping instructions provided. The contract is issued under solicitation SPE2DP-26-T-4391, with a required delivery date of August 3, 2026, and is managed by the Department of Defense’s Medical Supply Chain Pharm FSA, with Imerah Burnett designated as the primary point of contact.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Vaccine Antigen and Adjuvant ManufacturingThe contract pertains to the manufacture of bulk influenza vaccine antigens and adjuvanted formulations in compliance with current good manufacturing practices for use in clinical trials and emergency response scenarios. The work must adhere to stringent quality and regulatory standards to ensure safety and efficacy, with production intended to support public health preparedness and rapid deployment during outbreaks. The place of performance is designated as Washington, DC, with a delivery deadline for responses set for August 15, 2026. This subcontract falls under the NAICS code 325412, indicating classification within pharmaceutical and medicine manufacturing, and is issued by the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services. Participation requires capability to scale production while maintaining cGMP compliance across all stages of antigen and adjuvant formulation, with no set-aside provisions specified for small or disadvantaged businesses.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Supplier Opportunity – Ticagrelor 90mg Tablets in Bulk Bottles (500 or 1,000 Count) – Group I Only

Nac Pharmaceuticals (36E797)

POSTED

DEADLINE

Supplier Opportunity – Ticagrelor 60mg Tablets in Bulk Bottles (500 or 1,000 Count) – Group I Only

Nac Pharmaceuticals (36E797)

POSTED

DEADLINE